<DOC>
	<DOCNO>NCT00040898</DOCNO>
	<brief_summary>RATIONALE : The Chinese herbal medicine Sho-saiko-to contain ingredient may slow growth tumor cell stimulate person 's immune system help kill tumor cell . This may effective treatment follow hepatic artery embolization . PURPOSE : Phase II trial study effectiveness Sho-saiko-to follow hepatic artery embolization treat patient liver cancer .</brief_summary>
	<brief_title>Sho-Saiko-To Following Removal Liver Cancer By Embolization Treating Patients With Liver Cancer That Can Be Surgically Removed</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient unresectable hepatocellular carcinoma treat Sho-saiko-to ablation therapy embolization v historical control patient . - Compare liver function alpha fetoprotein level patient treat drug v historical control patient . - Compare intervention-free survival patient treat drug v historical control patient . OUTLINE : Beginning within 1 week first course ablation therapy embolization , patient receive oral Sho-saiko-to three time daily . Treatment Sho-saiko-to continue absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 78 patient accrue study within 18-24 month .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow condition : Histologically confirm unresectable hepatocellular carcinoma Serum alphafetoprotein ( AFP ) level great 500 ng/mL cirrhosis Serum AFP level great 500 ng/mL liver mass positive hepatitis B C serology Receiving ablation therapy embolization Extrahepatic disease allow No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,500/mm^3 Platelet count great 50,000/mm^3 Hemoglobin great 8.0 g/dL Hepatic : See Disease Characteristics Bilirubin le 2.0 mg/dL SGOT SGPT less 5 time upper limit normal ( ULN ) PT INR less 1.6 time ULN ( receive warfarin anticoagulation ) Albumin great 2.5 g/dL Renal : Creatinine le 1.8 mg/dL Pulmonary : DLCO least 50 % predict OR DLCO least 70 % predict total lung capacity le 80 % predict No significant lung disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix No uncontrolled infection pain No condition would significantly impair cognitive functioning study No overt psychosis , mental disability , incompetency would preclude study No lifethreatening illness prognosis poorer hepatocellular carcinoma PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent interferon Chemotherapy : No prior chemotherapy within 4 week initiate ablation therapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy within 4 week initiate ablation therapy Concurrent radiotherapy allow Surgery : See Disease Characteristics Other : See Disease Characteristics No prior ablation therapy No concurrent Shosaikoto constituent plant No concurrent anticancer medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
</DOC>